Zhang Jiayu, Lu Shiqi, Lu Tong, Han Donghui, Zhang Keying, Gan Lunbiao, Wu Xinjie, Li Yu, Zhao Xiaolong, Li Zhengxuan, Shen Yajie, Hu Sijun, Yang Fa, Wen Weihong, Qin Weijun
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Institute of Medical Research, Northwestern Polytechnical University, Xi'an, China.
Front Pharmacol. 2023 Jan 20;14:1121586. doi: 10.3389/fphar.2023.1121586. eCollection 2023.
Cancer-associated fibroblasts (CAFs) promote tumor progression through extracellular matrix (ECM) remodeling and extensive communication with other cells in tumor microenvironment. However, most CAF-targeting strategies failed in clinical trials due to the heterogeneity of CAFs. Hence, we aimed to identify the cluster of tumor-promoting CAFs, elucidate their function and determine their specific membrane markers to ensure precise targeting. We integrated multiple single-cell RNA sequencing (scRNA-seq) datasets across different tumors and adjacent normal tissues to identify the tumor-promoting CAF cluster. We analyzed the origin of these CAFs by pseudotime analysis, and tried to elucidate the function of these CAFs by gene regulatory network analysis and cell-cell communication analysis. We also performed cell-type deconvolution analysis to examine the association between the proportion of these CAFs and patients' prognosis in TCGA cancer cohorts, and validated that through IHC staining in clinical tumor tissues. In addition, we analyzed the membrane molecules in different fibroblast clusters, trying to identify the membrane molecules that were specifically expressed on these CAFs. We found that COL11A1+ fibroblasts specifically exist in tumor tissues but not in normal tissues and named them cancer-specific fibroblasts (CSFs). We revealed that these CSFs were transformed from normal fibroblasts. CSFs represented a more activated CAF cluster and may promote tumor progression through the regulation on ECM remodeling and antitumor immune responses. High CSF proportion was associated with poor prognosis in bladder cancer (BCa) and lung adenocarcinoma (LUAD), and IHC staining of COL11A1 confirmed their specific expression in tumor stroma in clinical BCa samples. We also identified that CSFs specifically express the membrane molecules LRRC15, ITGA11, SPHK1 and FAP, which could distinguish CSFs from other fibroblasts. We identified that CSFs is a tumor specific cluster of fibroblasts, which are in active state, may promote tumor progression through the regulation on ECM remodeling and antitumor immune responses. Membrane molecules LRRC15, ITGA11, SPHK1 and FAP could be used as therapeutic targets for CSF-targeting cancer treatment.
癌症相关成纤维细胞(CAFs)通过细胞外基质(ECM)重塑以及与肿瘤微环境中的其他细胞广泛通讯来促进肿瘤进展。然而,由于CAFs的异质性,大多数针对CAF的策略在临床试验中均告失败。因此,我们旨在鉴定促肿瘤CAF簇,阐明其功能并确定其特异性膜标志物以确保精准靶向。我们整合了来自不同肿瘤及相邻正常组织的多个单细胞RNA测序(scRNA-seq)数据集,以鉴定促肿瘤CAF簇。我们通过伪时间分析来分析这些CAFs的起源,并试图通过基因调控网络分析和细胞间通讯分析来阐明这些CAFs的功能。我们还进行了细胞类型反卷积分析,以研究这些CAFs的比例与TCGA癌症队列中患者预后之间的关联,并通过临床肿瘤组织中的免疫组化染色进行验证。此外,我们分析了不同成纤维细胞簇中的膜分子,试图鉴定在这些CAFs上特异性表达的膜分子。我们发现COL11A1+成纤维细胞特异性存在于肿瘤组织而非正常组织中,并将其命名为癌症特异性成纤维细胞(CSFs)。我们揭示这些CSFs是由正常成纤维细胞转化而来。CSFs代表一个更具活性的CAF簇,可能通过对ECM重塑和抗肿瘤免疫反应的调节来促进肿瘤进展。高CSF比例与膀胱癌(BCa)和肺腺癌(LUAD)的不良预后相关,并且COL11A1的免疫组化染色证实了其在临床BCa样本肿瘤基质中的特异性表达。我们还鉴定出CSFs特异性表达膜分子LRRC15、ITGA11、SPHK1和FAP,这些分子可将CSFs与其他成纤维细胞区分开来。我们鉴定出CSFs是一种肿瘤特异性成纤维细胞簇,处于活跃状态,可能通过对ECM重塑和抗肿瘤免疫反应的调节来促进肿瘤进展。膜分子LRRC15、ITGA11、SPHK1和FAP可作为针对CSF的癌症治疗的治疗靶点。